target directory

glp 1 receptor glp 1r clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

Directory type

target

Association rule

normalized field

NCT00978393

Source recordAI-normalized

A Randomised, Placebo-controlled, Double-blind, Incomplete Cross-over Design Trial to Evaluate the Effects of Liraglutide on Gastric Emptying, Energy Expenditure and Appetite, and to Evaluate Liraglutide Pharmacokinetics in Non-diabetic Obese Subjects

Liraglutide, a GLP-1 receptor agonist, is being evaluated for its effects on gastric emptying, energy expenditure, and appetite regulation in non-diabetic obese subjects. Given the rising prevalence of obesity and related metabolic disorders, this trial positions Novo Nordisk to potentially expand liraglutide's indications beyond diabetes management into obesity treatment. The competitive landscape includes other GLP-1 receptor agonists and weight management therapies, necessitating a robust differentiation strategy. Successful outcomes could enhance market share in the obesity treatment segment, which is projected to grow significantly. Diligence should focus on the trial's efficacy and safety data, as well as the regulatory landscape for obesity treatments.

AI analysis

Indication: Metabolism and Nutrition Disorder

Modality: small molecule

Target: GLP-1 receptor (GLP-1R)

Sponsor: Novo Nordisk A/S

Source URL: ClinicalTrials.gov

Source updated: Detailed source ingestion pending

Ingested: Jul 21, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: GLP-1 receptor (GLP-1R)

View original source fields

Condition raw: Metabolism and Nutrition Disorder, Obesity

Condition normalized: Metabolism and Nutrition Disorder, Obesity

Modality raw: small molecule

Modality normalized: small molecule

Target raw: GLP-1 receptor (GLP-1R)

Target normalized: GLP-1 receptor (GLP-1R)

Open report

NCT02016846

Source recordAI-normalized

Liraglutide Efficacy on Glucocorticoid Induced Hyperglycemia in Patients High Risk for Diabetes

The clinical trial investigates the efficacy of Liraglutide, a GLP-1 receptor agonist, in preventing glucocorticoid-induced hyperglycemia in patients at high risk for diabetes. Given the increasing prevalence of diabetes and the common use of glucocorticoids in various therapeutic regimens, successful outcomes could position Liraglutide as a critical preventive therapy in this patient population. The market potential is significant, particularly as there are currently no approved preventive therapies for glucocorticoid-induced diabetes. Competitive analysis indicates that while other GLP-1 receptor agonists exist, Liraglutide's specific application in this context may provide a unique market niche. Diligence should focus on the trial's recruitment status and any potential regulatory hurdles.

AI analysis

Indication: Glucocorticoid Induced Hyperglycemia

Modality: small molecule

Target: GLP-1 receptor (GLP-1R)

Sponsor: Rabin Medical Center

Source URL: ClinicalTrials.gov

Source updated: Detailed source ingestion pending

Ingested: Jul 21, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: GLP-1 receptor (GLP-1R)

NCT06939296

Source recordAI-normalized

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VCT220 Tablets in Overweight or Obese Participants

VCT220, a small molecule GLP-1 receptor agonist, is currently undergoing a Phase 3 clinical trial aimed at evaluating its efficacy and safety in overweight or obese adults. The obesity treatment market is rapidly expanding, driven by increasing prevalence rates and a growing focus on weight management solutions. VCT220's unique profile may position it competitively against existing GLP-1 therapies such as semaglutide and liraglutide. The trial's design, which includes a placebo-controlled approach and a robust participant enrollment of 840, suggests a significant investment in demonstrating clinical efficacy. Successful outcomes could lead to a strong market entry, particularly in regions with high obesity rates, such as China, where the trial is being conducted. However, the competitive landscape is intense, and Vincentage Pharma must navigate potential regulatory hurdles and market access challenges.

AI analysis

Indication: Obesity

Modality: small molecule

Target: GLP-1 receptor (GLP-1R)

Sponsor: Vincentage Pharma Co., Ltd

Source URL: ClinicalTrials.gov

Source updated: Detailed source ingestion pending

Ingested: Jul 08, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: GLP-1 receptor (GLP-1R)